Archrock Partners Reports First Quarter 2017 Results
May 04, 2017 10:02 am UTC| Business
HOUSTON, May 04, 2017 -- Archrock Partners, L.P. (NASDAQ:APLP) today reported a net loss of$4.3 million, or $0.07 per diluted common unit,for the first quarter of 2017, compared to a net loss of$14.0 million,or $0.22...
EMCORE Corporation Announces Financial Results for Second Quarter Ended March 31, 2017
May 04, 2017 10:02 am UTC| Business
Consolidated Q2 revenue of $32.6 millionConsolidated Q2 GAAP operating income of $1.8 million and Non-GAAP operating income of $3.7 millionGAAP EPS from continuing operations of $0.07 and Non-GAAP pre-tax EPS from...
EMCORE Corporation Announces Financial Results for Second Quarter Ended March 31, 2017
May 04, 2017 10:02 am UTC| Business
Consolidated Q2 revenue of $32.6 millionConsolidated Q2 GAAP operating income of $1.8 million and Non-GAAP operating income of $3.7 millionGAAP EPS from continuing operations of $0.07 and Non-GAAP pre-tax EPS from...
EMCORE Corporation Announces Financial Results for Second Quarter Ended March 31, 2017
May 04, 2017 10:02 am UTC| Business
Consolidated Q2 revenue of $32.6 millionConsolidated Q2 GAAP operating income of $1.8 million and Non-GAAP operating income of $3.7 millionGAAP EPS from continuing operations of $0.07 and Non-GAAP pre-tax EPS from...
McEwen Mining Announces Q1 2017 Operating & Financial Results
May 04, 2017 10:01 am UTC| Business
TORONTO, May 04, 2017 -- McEwen Mining Inc. (NYSE:MUX) (TSX:MUX) is pleased to report consolidated financial results for the first quarter ended March 31, 2017. Increased investments in exploration and project...
McEwen Mining Announces Q1 2017 Operating & Financial Results
May 04, 2017 10:01 am UTC| Business
TORONTO, May 04, 2017 -- McEwen Mining Inc. (NYSE:MUX) (TSX:MUX) is pleased to report consolidated financial results for the first quarter ended March 31, 2017. Increased investments in exploration and project...
May 04, 2017 10:01 am UTC| Business
EDISON, N.J., May 04, 2017 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced it is developing...
Threading Opportunity: How an India–EU FTA Could Reweave Textile Fortunes